The LUX‐Lung 7 trial demonstrated that afatinib slightly prolonged PFS, time‐to‐treatment failure, and ORR and exhibited a manageable tolerability profile when compared with gefitinib for first‐line treatment of EGFR mutation‐positive NSCLC.141. This evidence concerns the gene EGFR and non-small cell lung carcinoma.